tbuckley/cabot-search huggingface dataset:
Brief Report: Rituximab for the Treatment of Adult‐Onset IgA Vasculitis (Henoch‐Schönlein)
Authors: Federica Maritati, Roberta Fenoglio, Evangeline Pillebout, Giacomo Emmi, Maria L. Urban, Rossana Rocco, Maria Nicastro, Monia Incerti, Matteo Goldoni, Giorgio Trivioli, Elena Silvestri, Aladdin J. Mohammad, David Jayne, Per Eriksson, Mårten Segelmark, Pavel Novikov, Helen Harris, Dario Roccatello, Augusto Vaglio
Journal: Arthritis & Rheumatology (2017)

Objective Adult‐onset IgA vasculitis (Henoch‐Schönlein) (Ig AV ) is a rare systemic vasculitis characterized by IgA1‐dominant deposits. The treatment of adult‐onset Ig AV is controversial and is based on the combination of glucocorticoids and immunosuppressive agents, but many patients have refractory or relapsing disease despite treatment. Rituximab ( RTX ) is a B cell–depleting antibody of proven efficacy in antineutrophil cytoplasmic antibody–associated vasculitis. We undertook this study to test the efficacy and safety of RTX in a multicenter cohort of patients with adult‐onset Ig AV . Methods In this multicenter observational study, we included patients with adult‐onset Ig AV who had received RTX either for refractory/relapsing disease or because they had contraindications to conventional glucocorticoid/immunosuppressive therapy. We analyzed the rates of remission (defined on the basis of the Birmingham Vasculitis Activity Score [ BVAS ]) and relapse as well as the variations over time in estimated glomerular filtration rate ( GFR ), proteinuria, C‐reactive protein ( CRP ) level, BVAS , and prednisone dose. Results Twenty‐two patients were included; their median duration of follow‐up was 24 months (interquartile range 18–48 months). Sixteen patients received RTX as add‐on therapy and 6 as monotherapy. Twenty patients (90.9%) achieved remission, and 7 of those 20 patients (35%) had subsequent relapse of disease. There were significant reductions in 24‐hour proteinuria ( P &lt; 0.0001), CRP level ( P = 0.0005), BVAS ( P &lt; 0.0001), and prednisone dose ( P &lt; 0.0001) from RTX initiation through the last follow‐up visit; estimated GFR remained stable. RTX was generally well tolerated. One patient died after 60 months of follow‐up. Conclusion Our data suggest that RTX is an effective and safe therapeutic option for adult‐onset Ig AV .
Accuracy and prognostic significance of oncologists’ estimates and scenarios for survival time in a randomised Phase 2 trial of regorafenib in advanced gastric cancer
Authors: A. Vasista, A. Martin, N. Pavlakis, K. Sjoquist, S. Snow, D. Jonker, Y.J. Chua, R. Epstein, A. Bonaventura, M. Khasraw, S.C. Varma, N. Singhal, D.T. Ransom, F. Aubin, R. Burkes, H. Lim, F. Lemay, S. Begbie, M.R. Stockler, B. Kiely
Journal: Annals of Oncology (2017)
Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report
Authors: Pierre-Stéphane Gsell, Anton Camacho, Adam J Kucharski, Conall H Watson, Aminata Bagayoko, Séverine Danmadji Nadlaou, Natalie E Dean, Abdourahamane Diallo, Abdourahmane Diallo, Djidonou A Honora, Moussa Doumbia, Godwin Enwere, Elizabeth S Higgs, Thomas Mauget, Diakite Mory, Ximena Riveros, Fofana Thierno Oumar, Mosoka Fallah, Alhassane Toure, Andrea S Vicari, Ira M Longini, W J Edmunds, Ana Maria Henao-Restrepo, Marie Paule Kieny, Sakoba Kéïta
Journal: The Lancet Infectious Diseases (2017)

In March, 2016, a flare-up of Ebola virus disease was reported in Guinea, and in response ring vaccination with the unlicensed rVSV-ZEBOV vaccine was introduced under expanded access, the first time that an Ebola vaccine has been used in an outbreak setting outside a clinical trial. Here we describe the safety of rVSV-ZEBOV candidate vaccine and operational feasibility of ring vaccination as a reactive strategy in a resource-limited rural setting.Approval for expanded access and compassionate use was rapidly sought and obtained from relevant authorities. Vaccination teams and frozen vaccine were flown to the outbreak settings. Rings of contacts and contacts of contacts were defined and eligible individuals, who had given informed consent, were vaccinated and followed up for 21 days under good clinical practice conditions.Between March 17 and April 21, 2016, 1510 individuals were vaccinated in four rings in Guinea, including 303 individuals aged between 6 years and 17 years and 307 front-line workers. It took 10 days to vaccinate the first participant following the confirmation of the first case of Ebola virus disease. No secondary cases of Ebola virus disease occurred among the vaccinees. Adverse events following vaccination were reported in 47 (17%) 6-17 year olds (all mild) and 412 (36%) adults (individuals older than 18 years; 98% were mild). Children reported fewer arthralgia events than adults (one [<1%] of 303 children vs 81 [7%] of 1207 adults). No severe vaccine-related adverse events were reported.The results show that a ring vaccination strategy can be rapidly and safely implemented at scale in response to Ebola virus disease outbreaks in rural settings.WHO, Gavi, and the World Food Programme.
IDH wild type low grade gliomas: Who seeks shall find
Authors: A. Mandrioli, E. Franceschi, S. Minichillo, A. Mura, A. Tosoni, D. De Biase, E. Zunarelli, G. Lanza, D. Bartolini, E.M. Silini, G. Tallini, L. Cirillo, C. Bortolotti, D. Danieli, S. Bartolini, A. Paccapelo, A.A. Brandes
Journal: Annals of Oncology (2017)
Analysis of expression of immunomodulation factors in alveolar soft-part sarcoma: a retrospective study from the Spanish Group for Research on Sarcoma (GEIS)
Authors: N. Hindi, A. Fernandez-Serra, J. Martinez-Trufero, A. Carranza-Carranza, A. Lopez-Pousa, J. Lavernia, J.L. Arranz, R. López Alegret, J. Martinez-Garcia, C. Valverde Morales, J.M. Cano, M.A. Vaz, D.S. Moura, S. Bagué, R. Gonzalez-Campora, J.A. Lopez-Guerrero, J. Martin-Broto
Journal: Annals of Oncology (2017)
A novel circulating cell free DNA-based assay can predict tumor response to systematic chemotherapy
Authors: T. Toshima, T. Nagasaka, Y. Mori, T. Kawai, K. YASUI, T. Fuji, F. Taniguchi, K. Kimura, H. Kishimoto, Y. Umeda, A. Goel, T. Fujiwara
Journal: Annals of Oncology (2017)
Impact of the addition of metformin (Met) to abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) progressing on Abi treatment: A phase II pilot study
Authors: M. Mark, D. Klingbiel, U. Mey, R. Winterhalder, C. Rothermundt, S. Gillessen, R. von Moos, G. Manetsch, R. Cathomas
Journal: Annals of Oncology (2017)
Emergence of pregnancy-related listeriosis amongst ethnic minorities in England and Wales
Authors: P Mook, K A Grant, C L Little, G Kafatos, I  A Gillespie
Journal: Eurosurveillance (2010)

Listeriosis is a rare but severe food-borne disease that predominantly affects pregnant women, the unborn, newborns, the elderly and immunocompromised people. Following a large outbreak in the 1980s, specific food safety advice was provided to pregnant women and the immunocompromised in the United Kingdom. Following two coincident yet unconnected cases of pregnancy-related listeriosis in eastern European women in 2008, a review of the role of ethnicity in pregnancy-related listeriosis in England and Wales was undertaken in 2009. Cases reported to the national listeriosis surveillance scheme were classified as 'ethnic', belonging to an ethnic minority, or 'non-ethnic' based on their name, and trends were examined. Between 2001 and 2008, 1,510 cases of listeriosis were reported in England and Wales and, of these, 12% were pregnancy-related cases. The proportion of pregnancy-related cases classified as ethnic increased significantly from 16.7% to 57.9% (chi-square test for trend p=0.002). The reported incidence among the ethnic population was higher than that among the non-ethnic population in 2006, 2007 and 2008 (Relative Risk: 2.38, 95% confidence interval: 1.07 to 5.29; 3.82, 1.82 to 8.03; 4.33, 1.74 to 10.77, respectively). This effect was also shown when analysing data from January to September 2009, using extrapolated live births as denominator. Increased immigration and/or economic migration in recent years appear to have altered the population at risk of pregnancy-related listeriosis in England and Wales. These changes need to be taken into account in order to target risk communication strategies appropriately.
Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors
Authors: Ahmad Alhuraiji, Hagop Kantarjian, Prajwal Boddu, Farhad Ravandi, Gautam Borthakur, Courtney DiNardo, Naval Daver, Tapan Kadia, Naveen Pemmaraju, Sherry Pierce, Guillermo Garcia‐Manero, William Wierda, Srdan Verstovsek, Elias Jabbour, Jorge Cortes
Journal: American Journal of Hematology (2017)

Additional cytogenetic abnormalities (ACA) are considered a high risk feature in chronic myeloid leukemia (CML). However, its prognostic significance at the time of diagnosis in the setting of new tyrosine kinase inhibitors (TKIs) is less well understood. Patients with CML in CP with or without ACA at diagnosis treated with frontline TKIs in prospective clinical trials were analyzed for outcomes. Among 603 patients treated, 29 (5%) had ACA. Patients with ACA included 2 of 72 (2.8%) treated with imatinib 400 mg, 9 of 207 (4.3%) with imatinib 800 mg, 10 of 148 (6.7%) with dasatinib, 6 of 126 (4.7%) with nilotinib, and 2 of 50 (4%) with ponatinib. There was a significantly higher rate of complete cytogenetic response (CCyR) at 6 months in patients without ACA (P = .02). However cumulative CCyR and major molecular response (MMR) rates were not different. Similarly, MR4.0 and MR4.5 rates were similar for both groups; two CML-ACA patients maintained MR 4.5 for at least 2 years. At 5 years, ACA at diagnosis did not significantly impact transformation-free, failure-free, event-free, or overall survival expectations. Acknowledging small sample size estimates, response rates and survival outcomes were comparable in CP with ACA irrespective of whether chromosomal abnormalities were "major route" or other. The presence of ACA at diagnosis does not confer worse prognosis for patients with CML treated with TKI. Thus, the presence of ACA at diagnosis should not alter treatment strategies in these patients.
Surveillance de la tuberculose en Irlande
Authors: A Smith, D Igoe, D O’Flanagan, T Holohan
Journal: Eurosurveillance (2000)

En Irlande, les premieres donnees non aggregees sur la tuberculose ont ete recueillies en 1998. Au total, 424 cas ont ete declares (taux de 11,7/100 000 habitants) dont 241 cas avec une culture positive et 122 cas pulmonaires avec un frottis d’expectoration positif. Seuls 35 cas etaient d’origine etrangere et aucun cas de multiresistance n’a ete identifie.
Double-blind, randomized phase III study to compare the efficacy and safety of trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early breast cancer (EBC)
Authors: F.J. Esteva, Y. Baranau, V. Baryash, A. Manikhas, V. Moiseyenko, G. Dzagnidze, E. Zhavrid, D. Boliukh, D. Stroyakovskiy, J. Pikiel, A. Eniu, D. Komov, Z. Zautashvili, G. Morar-Bolba, R.K. Li, I. Lifirenko, A. Rusyn, S.J. Lee, S. Yu, J. Stebbing
Journal: Annals of Oncology (2017)
La surveillance de la rage, l’évolution de la rage animale et la prophylaxie post-exposition humaine en Pologne, 1990-2004
Authors: M Sadkowska-Todys, M Rosinska, M Smreczak, M Czerwinski, J F Zmudzinski
Journal: Eurosurveillance (2005)

L’article suivant decrit les recents changements dans la situation epizootique et epidemiologique de la rage en Pologne. Une analyse des donnees de surveillance en routine des cas animaux et des traitements post-exposition chez l’homme a ete realisee afin d’etudier l’impact de l’introduction d’un vaccin sur culture cellulaire pour l’homme et la mise en œuvre d’un programme de vaccination des renards. Le succes du programme d’immunisation des animaux sauvages s’est confirme les trois dernieres annees, avec la reduction d’un facteur neuf des cas de rage animale. Cependant, actuellement, la tendance a la baisse des cas de rage animale n’a pas eu de consequence sur la frequence d’administration d’une prophylaxie post-exposition chez l’homme. De plus, deux cas de rage humaine autochtone sont survenus chez des patients qui n’avaient pas recu le vaccin post-exposition. Ces cas confirment que la rage doit continuer a etre consideree comme un probleme de sante publique en Pologne.
Acquisition or Loss of Gene Mutations Occurs in Relapsed Pediatric Acute Myeloid Leukemia: A Comparative Analysis of Paired Matched Diagnosis and Relapse Bone Marrow Samples
Authors: Der-Cherng Liang, Hsi-Che Lui, Chao-Ping Yang, Tang-Her Jaing, Iou-Jih Hung, Ting-Chi Yeh, Yu-Shu Shih, Yu-Hui Huang, Tung-Huei Lin, Lee-Yung Shih
Journal: Blood (2012)
Ongoing phase 1 trial of SL-801, a novel XPO-1 inhibitor, in patients with advanced solid tumors; Interim results
Authors: J. Wang, J. Nemunaitis, G. Chiorean, P. Lorusso, K. Courtney, A. Olguin, J. Bullington, S. Shemesh, J. Chen, C. Brooks, T.M. Bauer
Journal: Annals of Oncology (2017)
Comparison of tumor mutational burden (TMB) in relevant molecular subsets of metastatic urothelial cancer (MUC)
Authors: S.K. Pal, N. Agarwal, T.K. Choueiri, P.J. Stephens, J.S. Ross, V.A. Miller, S.M. Ali, J. Chung, P. Grivas
Journal: Annals of Oncology (2017)
Screening of NSCLC samples from Chinese lung cancer patients for activating rearrangements of the <i>ALK, RET</i>, and <i>ROS1</i> genes.
Authors: Li-Mou Zheng, David B. Whyte, Li Ruan, Roman Song, Luo Fei, Nancy Yang, Caicun Zhou
Journal: Journal of Clinical Oncology (2013)

e22066 Background: The ALK, RET, and ROS1 genes are involved in gene rearrangements in a fraction of non-small cell lung cancers. The resulting oncogenic fusion genes define molecular sub-types of NSCLC with distinct sensitivities to treatment with various kinase inhibitors. We developed real-time reverse transcriptase PCR assays to detect rearrangements of ALK, RET, and ROS1 in FFPE lung cancer tissue. Methods: mRNA from NSCLC FFPE tissue samples was reverse transcribed to cDNA. Multiplex quantitative PCR was performed to detect 9 variants of EML4-ALK fusions, 9 variants of RET fusions and 14 variants of ROS1 fusions. A total of 409 samples were analyzed: 267 were classified as adenocarcinoma, 104 as squamous cell carcinoma and 38 had undetermined histology. EGFR and KRAS mutation status is unknown. The junctions of fusion-positive samples were sequenced by Sanger sequencing. Results: Among the 409 NSCLC specimens tested the frequency was 5.4% (22/409) for EML4-ALK fusions, 1.5% (6/409) for RET fusions, and 2.2% (9/409) for ROS1 fusions. EML4-ALK fusions were more prevalent in patients that were less than 60 years old (9.1% versus 2.0%, p= 0.004). The TNM stage was not correlated with the presence of any of the fusions. The table below lists the frequencies for specific rearrangements as determined by sequencing the real-time PCR products. Conclusions: Real-time PCR assays based on cDNA from FFPE tissue can identify patients with ALK, RET and ROS1 fusion genes. The ALK, RET and ROS1 assays will allow selection of patients most likely to respond to therapies that specifically target these cancer drivers. Further clinical testing of NSCLC patients in the Chinese population will be performed to support SFDA registration of these assays in China. [Table: see text]
Effect of patient choice and hospital competition on service configuration and technology adoption within cancer surgery: a national, population-based study
Authors: Ajay Aggarwal, Daniel Lewis, Malcolm Mason, Arnie Purushotham, Richard Sullivan, Jan van der Meulen
Journal: The Lancet Oncology (2017)

There is a scarcity of evidence about the role of patient choice and hospital competition policies on surgical cancer services. Previous evidence has shown that patients are prepared to bypass their nearest cancer centre to receive surgery at more distant centres that better meet their needs. In this national, population-based study we investigated the effect of patient mobility and hospital competition on service configuration and technology adoption in the National Health Service (NHS) in England, using prostate cancer surgery as a model.We mapped all patients in England who underwent radical prostatectomy between Jan 1, 2010, and Dec 31, 2014, according to place of residence and treatment location. For each radical prostatectomy centre we analysed the effect of hospital competition (measured by use of a spatial competition index [SCI], with a score of 0 indicating weakest competition and 1 indicating strongest competition) and the effect of being an established robotic radical prostatectomy centre at the start of 2010 on net gains or losses of patients (difference between number of patients treated in a centre and number expected based on their residence), and the likelihood of closing their radical prostatectomy service.Between Jan 1, 2010, and Dec 31, 2014, 19 256 patients underwent radical prostatectomy at an NHS provider in England. Of the 65 radical prostatectomy centres open at the start of the study period, 23 (35%) had a statistically significant net gain of patients during 2010-14. Ten (40%) of these 23 were established robotic centres. 37 (57%) of the 65 centres had a significant net loss of patients, of which two (5%) were established robotic centres and ten (27%) closed their radical prostatectomy service during the study period. Radical prostatectomy centres that closed were more likely to be located in areas with stronger competition (highest SCI quartile [0·87-0·92]; p=0·0081) than in areas with weaker competition. No robotic surgery centre closed irrespective of the size of net losses of patients. The number of centres performing robotic surgery increased from 12 (18%) of the 65 centres at the beginning of 2010 to 39 (71%) of 55 centres open at the end of 2014.Competitive factors, in addition to policies advocating centralisation and the requirement to do minimum numbers of surgical procedures, have contributed to large-scale investment in equipment for robotic surgery without evidence of superior outcomes and contributed to the closure of cancer surgery units. If quality performance and outcome indicators are not available to guide patient choice, these policies could threaten health services' ability to deliver equitable and affordable cancer care.National Institute for Health Research.
Interim safety and clinical activity of nivolumab (Nivo) in combination with S-1/capecitabine plus oxaliplatin in patients (pts) with previously untreated unresectable advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: part 1 study of ATTRACTION-04 (ONO-4538-37)
Authors: Y-K. Kang, K. Kato, H.C. Chung, K. Minashi, K-W. Lee, H. Cho, W.K. Kang, Y. Komatsu, M. Tsuda, K. Yamaguchi, H. Hara, S. Fumita, M. Azuma, N. Boku, L-T. Chen
Journal: Annals of Oncology (2017)
Implications of routine NGS testing for daily clinical practice – the Zurich experience with the OFA panel
Authors: C. Britschgi, C. Diehl, M. Rechsteiner, N. Valtcheva, S. Freiberger, C. Wong, A. Curioni-Fontecedro, A. Siebenhüner, A. Christiansen, N. Velizheva, Q. Zhong, U. Wagner, R. Stahel, H. Moch, P. Wild
Journal: Annals of Oncology (2017)
Surveillance for hepatitis B virus infection in pregnant women in Greece shows high rates of chronic infection among immigrants and low vaccination-induced protection rates: preliminary results of a single center study
Authors: I S Elefsiniotis, I Glynou, I Zorou, I Magaziotou, H Brokalaki, E Apostolopoulou, E Vezali, H Kada, G Saroglou
Journal: Eurosurveillance (2009)

Epidemiological data on the prevalence of serological markers of hepatitis B virus (HBV) infection in pregnant women in Greece are limited. We evaluated the prevalence of HBV serological markers in a multinational population of pregnant women in Athens, Greece. The overall prevalence of hepatitis B surface antigen (HbsAg) was 4.1% with the highest rates among Albanian immigrants (12%). Relatively low vaccination-induced protection rates (32.5%) were observed, a finding suggesting that surveillance and immunisation programmes targeted at pregnant women are necessary.
Is African-America race (AAR) a risk factor for failure in prostate cancer (PCa)?
Authors: M. J. Mann, M. C. Benson, J. M. McKiernan
Journal: Journal of Clinical Oncology (2007)

1515 Background: There is much disagreement as to whether AAR is an independent negative risk factor in biochemical disease-free survival (BCDFS) of PCa. Much of the literature suggests that AAR is a negative risk factor of BCDFS. However, the past decade has seen improvements in treatments that may have affected outcomes in PCa. Thus, we sought to determine if AAR is an independent risk factor for BCDFS in a modern cohort of PCa patients. Methods: A retrospective review of The Columbia Urologic Oncology Database was performed. From ‘91-‘06, 2,747 patients underwent radical prostatectomy and did not receive adjunctive treatment. Of these, 252 (9%) patients were AAR, and 2495 were not of African-American Race (NAAR). Of the NAAR patients, 1,907 (69%) were Caucasian, and 588 (21%) were of other or unknown race. BCDFS was defined as time to first rise in PSA (&gt;0.1ng/mL) or use of secondary therapy after surgery. Patients were stratified based on race (AAR vs NAAR) and year of surgery. BCDFS was evaluated using Kaplan-Meier (KM) analysis with log- rank test. Multivariate Cox regression models were fit and interaction terms were tested with Wall’s test to determine the significance of AAR on BCDFS over 3 time periods (91–95, 96–00, and 01–06). Results: The patients had a median age 61.9 yrs, pathological Gleason sum (GS) 7, and mean PSA 7.7. In KM analysis, AAR was a negative risk factor of BCDFS (p&lt;0.01) over all time periods, had lower mean age at surgery (p&lt;0.01), higher pre-operative PSA (p&lt;0.01), and higher GS (p&lt;0.01). Not surprisingly, once PSA, GS, and stage were controlled across time cohorts, AAR lost significance as a risk factor (p=0.46). When Wall’s test was used to compare the results of a multivariate analysis controlling for the same variables and stratified by time, it was found that outcomes improved over time in patients of AAR and NAAR (p&lt;0.01), but there was no difference between the two groups (p=0.99). Conclusions: Despite previous reports that AAR is an independent negative predictor of outcome, it only appeared to be a negative risk factor in univariate analyses. Despite higher PSA, and GS, AAR was no longer a significant risk factor. Additionally, when stratified by time, patients in more contemporary cohorts had improved outcomes, with no differences between AAR and NAAR patients. No significant financial relationships to disclose.